Abbott Laboratories operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Abbott Laboratories with three other companies in this sector in UNITED STATES : Bristol-Myers Squibb Company (2020 sales of $42.52 billion of which 28% was Prioritized Brands-Revlimid), Eli Lilly and Company ($24.54 billion of which 29% was Oncology-Verzenio & Other), and Pfizer Inc. ($41.91 billion of which 26% was Oncology).

Sales Analysis. During the second quarter of 2021, sales at Abbott Laboratories totalled $10.22 billion. This is an increase of 39.5% from the $7.33 billion in sales at the company during the second quarter of 2020. This was the largest same quarter increase in sales since the fourth quarter of 2017. During the first two quarters of 2021, sales totalled $20.68 billion, which is 37.4% higher than through the first two quarters of 2020. During the year ended December of 2020, sales at Abbott Laboratories were $34.61 billion. This is an increase of 8.5% versus 2019, when the company's sales were $31.90 billion. This was the fifth consecutive year of sales increases at Abbott Laboratories (and since 2015, sales have increased a total of 70%). Sales of Diagnostics Products saw an increase that was more than double the company's growth rate: sales were up 40.1% in 2020, from $7.71 billion to $10.81 billion. Abbott Laboratories also saw significant increases in sales in Other (up 15.8% to $66.00 million) . Not all segments of Abbott Laboratories experienced an increase in sales in 2020: sales of Established Pharmaceutical Products fell 4.1% to $4.30 billion. Abbott Laboratories also experienced decreases in sales in Medical Devices (down 3.7% to $11.79 billion) .